Drug intelligence / Profile preview

TSC-102-A01

Development stage: Unknown
Lead developer: TScan Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TSC-102-A01 is an allogeneic, donor-derived T cell receptor (TCR)-engineered T cell (TCR-T) therapy candidate developed by TScan Therapeutics. It is designed to target CD45, a protein broadly expressed in hematopoietic cells but absent in non-hematopoietic tissues, specifically for patients with the HLA-A*01:01 allele. The therapy is intended to eliminate residual cancer and prevent relapse in patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation (HCT). By targeting a lineage-specific antigen, TSC-102-A01 aims to provide a potent anti-leukemic effect while minimizing off-target toxicity to non-hematopoietic organs.

Targets

CD45/HLA-A*01:01 (CD45 peptide–HLA-A*01:01 complex)

Beyond the preview

Go deeper on TSC-102-A01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSC-102-A01.

Explore the full profile